Amgen Inc.’s blood-enhancing drug EPO has helped millions of anemia patients, but Lance Armstrong and other top cyclists have turned the medicine into a byword for doping. Now a growing number of pharmaceutical companies are trying to prevent their drugs from the same fate, the New York Times reports.